NCT04340050View on ClinicalTrials.gov

COVID-19 Convalescent Plasma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

December 23, 2020

Study Completion Date

December 23, 2020

Conditions
Coronavirus
Interventions
BIOLOGICAL

anti-SARS-CoV-2 convalescent plasma

Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours

Trial Locations (1)

60637

University of Chicago Medicine, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT04340050 - COVID-19 Convalescent Plasma | Biotech Hunter | Biotech Hunter